ReP USP - Resultado da busca

Artigo de periodico
Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: rationale and design of the ticagrelor in patients with ST-elevation myocardial infarction treated with thrombolysis (TREAT) trial (2018)
Berwanger, Otavio; Nicolau, José Carlos
Source: American heart journal. Unidade: FM
Subjects: FÁRMACOS (SISTEMA CARDIOVASCULAR), INFARTO DO MIOCÁRDIO, SÍNDROME CORONARIANA AGUDA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BERWANGER, Otavio e NICOLAU, José Carlos. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: rationale and design of the ticagrelor in patients with ST-elevation myocardial infarction treated with thrombolysis (TREAT) trial. American heart journal, v. 202, p. 89-96, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.ahj.2018.02.017. Acesso em: 17 out. 2024.
APA
Berwanger, O., & Nicolau, J. C. (2018). Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: rationale and design of the ticagrelor in patients with ST-elevation myocardial infarction treated with thrombolysis (TREAT) trial. American heart journal, 202, 89-96. doi:10.1016/j.ahj.2018.02.017
NLM
Berwanger O, Nicolau JC. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: rationale and design of the ticagrelor in patients with ST-elevation myocardial infarction treated with thrombolysis (TREAT) trial [Internet]. American heart journal. 2018 ; 202 89-96.[citado 2024 out. 17 ] Available from: https://doi.org/10.1016/j.ahj.2018.02.017
Vancouver
Berwanger O, Nicolau JC. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: rationale and design of the ticagrelor in patients with ST-elevation myocardial infarction treated with thrombolysis (TREAT) trial [Internet]. American heart journal. 2018 ; 202 89-96.[citado 2024 out. 17 ] Available from: https://doi.org/10.1016/j.ahj.2018.02.017
Artigo de periodico
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) (2018)
Giugliano, Robert P.; Nicolau, Jose Carlos
Source: Circulation. Unidade: FM
Subjects: DIABETES MELLITUS, DOENÇAS CARDIOVASCULARES, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIUGLIANO, Robert P. e NICOLAU, Jose Carlos. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, v. 137, n. 15, p. 1571-0, 2018Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.117.030950. Acesso em: 17 out. 2024.
APA
Giugliano, R. P., & Nicolau, J. C. (2018). Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, 137( 15), 1571-0. doi:10.1161/CIRCULATIONAHA.117.030950
NLM
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 out. 17 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Vancouver
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 out. 17 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Artigo de periodico
Anti-MOG (Myelin Oligodendrocyte Glycoprotein)-Positive Severe Optic Neuritis with Optic Disc Ischaemia and Macular Star (2015)
Moura, Frederico Castelo; Leite, Claudia da Costa ; Monteiro, Mário Luiz Ribeiro
Source: Neuro-ophthalmology. Unidade: FM
Subjects: ESCLEROSE MÚLTIPLA, TESTES SOROLÓGICOS, IMAGEM POR RESSONÂNCIA MAGNÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MOURA, Frederico Castelo e LEITE, Claudia da Costa e MONTEIRO, Mário Luiz Ribeiro. Anti-MOG (Myelin Oligodendrocyte Glycoprotein)-Positive Severe Optic Neuritis with Optic Disc Ischaemia and Macular Star. Neuro-ophthalmology, v. 39, n. 6, p. 285-288, 2015Tradução . . Disponível em: https://doi.org/10.3109/01658107.2015.1084332. Acesso em: 17 out. 2024.
APA
Moura, F. C., Leite, C. da C., & Monteiro, M. L. R. (2015). Anti-MOG (Myelin Oligodendrocyte Glycoprotein)-Positive Severe Optic Neuritis with Optic Disc Ischaemia and Macular Star. Neuro-ophthalmology, 39( 6), 285-288. doi:10.3109/01658107.2015.1084332
NLM
Moura FC, Leite C da C, Monteiro MLR. Anti-MOG (Myelin Oligodendrocyte Glycoprotein)-Positive Severe Optic Neuritis with Optic Disc Ischaemia and Macular Star [Internet]. Neuro-ophthalmology. 2015 ; 39( 6): 285-288.[citado 2024 out. 17 ] Available from: https://doi.org/10.3109/01658107.2015.1084332
Vancouver
Moura FC, Leite C da C, Monteiro MLR. Anti-MOG (Myelin Oligodendrocyte Glycoprotein)-Positive Severe Optic Neuritis with Optic Disc Ischaemia and Macular Star [Internet]. Neuro-ophthalmology. 2015 ; 39( 6): 285-288.[citado 2024 out. 17 ] Available from: https://doi.org/10.3109/01658107.2015.1084332

USP Schools

ReP

Filtros

Authors

Subjects

Funding Agencies